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Measurements, at least of whole-body balances and
exchangeable cations, are needed to understand when and
why and how the famous Edelman equation needs
augmentation. Until then, it might as well be kept simple,
yes, that was my point. Like others, I have found good use
of the simple form,7 but I am prepared that it will not
always suffice.8
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To the Editor: Based on rodent tissue deposition data,
Slatopolsky et al.1 allude to potential hepatic effects with
long-term use of lanthanum carbonate in end-stage renal
disease patients. Continuing vigilance and safety monitoring
are essential for any new drug, but existing animal and
human safety data do not indicate a specific concern in
relation to the liver toxicity for lanthanum. The liver is the
primary excretory organ for lanthanum, which is highly
protein bound. It is taken up and eliminated by the
transferrin receptor–endocytosis–lysosomal–biliary canalicu-
lar system.2 Thus, lanthanum appears to have an innocent
localization, being confined to the hepatic endosomal/
lysosomal compartment during passage through the liver
into bile. As a result of this transcellular transport mechan-
ism, lanthanum carbonate given to rats at a dose of 1500 mg/
kg body weight for 78 weeks resulted in a low steady-state
concentration of 2.471.5 mg/g (17711 nmol/g) of liver
tissue, from week 26 onwards. In comparison, the steady-
state liver concentration of copper and iron in normal
man vary around 32 mg/g (503 nmol/g) and 560 mg/g
(710 000 nmol/g), respectively. Published tissue deposition
studies in uremic rats1,2 have consistently demonstrated that
liver exposure is at trace levels (o2.6 mg/g (o19 nmol/g)),
with no evidence of adverse histologic or ultrastuctural
changes reported. Stringent genetic toxicity and lifetime
rodent safety studies conducted at high doses have similarly
failed to identify any toxic, genotoxic, or carcinogenic
potential in relation to the liver.3 Controlled clinical studies
to date have not shown a signal for adverse hepatic effects
owing to lanthanum treatment. In a recent analysis of
hepatobiliary adverse events and liver function data from
over 2000 dialysis patients participating in Phase III trials of
lanthanum carbonate (doses up to 3.75 g/day) for up to 2
years, we found no increase in hepatobiliary adverse events or
raised liver enzyme activities resulting from treatment
(Table 1).4
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Table 1 | Liver enzyme activities (mean7s.d.) after 1 and 2
years of treatment with lanthanum carbonate or standard
therapy
Lanthanum
carbonate
(n=682)
Standard
therapy
(n=677) P-value
1 year
ALT (U/l) 17.8712.2 17.3712.5 —
Change from baseline 1.3715.9 0.03713.0 0.197
GGT (U/l) 43.9781.7 48.6776.2 —
Change from baseline 0.5747.1 4.9744.4 0.107
2 years
ALT (U/l) 17.0710.4 15.5717.6 —
Change from baseline 2.17715.1 1.16711.0 0.421
GGT (U/l) 42.8784.2 44.6768.1 —
Change from baseline 0.6749.7 2.8743.5 0.425
ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase.
Patients received lanthanum carbonate (doses up to 3 g/day) or standard therapy
(previous phosphate binder) in a randomized trial for 2 years. Liver-related adverse
events occurred in 28 patients (4%) on lanthanum carbonate and 63 patients (7%)
on standard therapy, of which none was considered likely to be related to treatment
(values adjusted for treatment exposure).
Normal values: ALTo30 U/l (men) and o19 U/l (women); GGT 0–51 U/l.
Statistical comparisons were made using a mixed effect model to compare the
change from baseline. Reproduced from Hutchison et al.4
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